ArticleClinical rheumatology2025
Characterization of Patients with Macrophage Activation Syndrome Secondary to Systemic Juvenile Idiopathic Arthritis.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The Asia-Pacific League of Associations for Rheumatology Consensus Recommendations on the Management of Systemic Juvenile Idiopathic Arthritis (Juvenile Still's Disease).International journal of rheumatic diseases · 2026Guideline
- Early intensification versus step-up biologic strategies in systemic juvenile idiopathic arthritis: a Bayesian network meta-analysis of remission and safety outcomes.Pediatric rheumatology online journal · 2026Pooled it
- Risk factors for macrophage activation syndrome in systemic juvenile idiopathic arthritis: a systematic review and meta-analysis.Frontiers in pediatrics · 2025Pooled it
- Article
- Early IL-1 inhibition and long-term remission in childhood-onset Still's disease: a real-world cohort study.Frontiers in pediatrics · 2026Article
- Highlights on the Contribution of Gut Microbiota to Immune-Mediated Diseases in Childhood.Mediterranean journal of hematology and infectious diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe study aimed to analyze the clinical and laboratory characteristics of patients with systemic juvenile idiopathic arthritis (sJIA) who developed macrophage activation syndrome (MAS) and identify factors linked to MAS occurrence.
methodsPatients with sJIA, diagnosed based on internationally recognized criteria, participated in the research. Retrospective clinical and laboratory data from inflammatory episodes complicated by MAS were evaluated. The Hemophagocytic Syndrome diagnostic score was calculated to assess its utility on pediatric population.
resultsThe study included 23 patients with systemic juvenile idiopathic arthritis (sJIA), of whom 7 (30%) experienced macrophage activation syndrome (MAS) during their disease course. At the time of admission, patients who developed MAS exhibited elevated liver enzymes: ALT (Median = 43, IQR: 25 - 473 vs. Median = 14, IQR: 12 - 30, p = 0.006) and AST (Median = 66, IQR: 51 - 666 vs. Median = 27, IQR: 25 - 33, p = 0.024). Similarly, during hospitalization, patients with MAS showed significantly higher AST levels (Median = 534, IQR: 111 - 1130 vs. Median = 31, IQR: 26 - 42, p = 0.020) and ALT levels (Median = 160, IQR: 46 - 559 vs. Median = 23, IQR: 14 - 48, p = 0.024). Additionally, they experienced a greater decrease in platelet count (Median = 119, IQR: 39 - 209 vs. Median = 306, IQR: 249 - 457, p = 0.004), higher white blood cell counts (Median = 29, IQR: 17 - 36 vs. Median = 18, IQR: 14 - 26, p = 0.021), and elevated D-dimer levels (Median = 16,800, IQR: 5,190 - 34,000 vs. Median = 1,851, IQR: 1,352 - 2,189, p = 0.006). No association was found between MAS and gender, muscle pain, hemophagocytosis in bone marrow aspirate, erythematous rash, or conjunctivitis. The Hemophagocytic Syndrome diagnostic score (HS score) at the optimal cutoff of 169 achieved a sensitivity of 86% and a specificity of 88%.
conclusionsThe findings underscore the significance of recognizing specific clinical and laboratory indicators, such as thrombocytopenia and elevated markers like D-dimers and liver enzymes, to identify sJIA patients at heightened risk for MAS. Prompt diagnosis and intervention are crucial to improving outcomes in this patient group. Key Points • The study identifies thrombocytopenia, elevated D-dimers, hypertriglyceridemia, and elevated liver enzymes (AST, ALT) as key laboratory predictors of macrophage activation syndrome (MAS) in systemic juvenile idiopathic arthritis (sJIA) patients. • Laboratory abnormalities, including high ferritin levels, thrombocytopenia, and impaired liver function, were highlighted as critical markers for distinguishing MAS from active sJIA. • Clinical factors such as erythematous rash and conjunctivitis were inversely associated with MAS occurrence, aiding differential diagnosis. • The findings emphasize the importance of early detection and routine monitoring of laboratory parameters to prevent delays in MAS diagnosis and improve patient outcome.
Indexed as
Identifiers
40146446What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.